| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).
|
J Natl Cancer Inst
|
2004
|
2.79
|
|
2
|
Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
|
J Clin Oncol
|
2002
|
2.28
|
|
3
|
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).
|
Int J Gynecol Cancer
|
2011
|
2.09
|
|
4
|
Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.
|
Clin Cancer Res
|
2012
|
1.51
|
|
5
|
Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer.
|
J Oncol
|
2011
|
1.15
|
|
6
|
Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group.
|
Acta Oncol
|
2005
|
1.13
|
|
7
|
Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy.
|
Int J Radiat Oncol Biol Phys
|
2012
|
1.04
|
|
8
|
The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
|
Lung Cancer
|
2012
|
1.02
|
|
9
|
Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer.
|
Acta Oncol
|
2007
|
1.02
|
|
10
|
The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
|
Int J Gynecol Cancer
|
2009
|
1.00
|
|
11
|
Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region.
|
Int J Radiat Oncol Biol Phys
|
2006
|
0.99
|
|
12
|
The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer.
|
BMC Cancer
|
2012
|
0.98
|
|
13
|
Epidermal growth factor receptor analyses in colorectal cancer: a comparison of methods.
|
Int J Oncol
|
2006
|
0.98
|
|
14
|
Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer.
|
Virchows Arch
|
2010
|
0.98
|
|
15
|
Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.
|
Int J Oncol
|
2008
|
0.96
|
|
16
|
Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab.
|
J Ovarian Res
|
2012
|
0.95
|
|
17
|
PET/CT and histopathologic response to preoperative chemoradiation therapy in locally advanced rectal cancer.
|
Dis Colon Rectum
|
2007
|
0.94
|
|
18
|
The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial.
|
Int J Colorectal Dis
|
2011
|
0.94
|
|
19
|
Clinical implications of genetic variations in the VEGF system in relation to colorectal cancer.
|
Pharmacogenomics
|
2011
|
0.92
|
|
20
|
The importance of -460 C/T and +405 G/C single nucleotide polymorphisms to the function of vascular endothelial growth factor A in colorectal cancer.
|
J Cancer Res Clin Oncol
|
2009
|
0.91
|
|
21
|
The importance of applicator design for intraluminal brachytherapy of rectal cancer.
|
Med Phys
|
2006
|
0.91
|
|
22
|
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer.
|
BMC Cancer
|
2011
|
0.91
|
|
23
|
Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients.
|
Int J Gynecol Cancer
|
2011
|
0.90
|
|
24
|
Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer.
|
Int J Gynecol Cancer
|
2009
|
0.89
|
|
25
|
Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer.
|
Breast Cancer Res Treat
|
2012
|
0.89
|
|
26
|
Identification of chromosome aberrations in sporadic microsatellite stable and unstable colorectal cancers using array comparative genomic hybridization.
|
Cancer Genet
|
2011
|
0.88
|
|
27
|
Improved classification of epithelial ovarian cancer: results of 3 danish cohorts.
|
Int J Gynecol Cancer
|
2011
|
0.87
|
|
28
|
Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study.
|
Anticancer Res
|
2014
|
0.87
|
|
29
|
Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors.
|
Clin Cancer Res
|
2008
|
0.87
|
|
30
|
Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors.
|
Dis Colon Rectum
|
2007
|
0.86
|
|
31
|
Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
|
Int J Cancer
|
2014
|
0.86
|
|
32
|
Factors influencing reproducibility of tumour regression grading after high-dose chemoradiation of locally advanced rectal cancer.
|
Histopathology
|
2011
|
0.85
|
|
33
|
Pretreatment HIF-1α and GLUT-1 expressions do not correlate with outcome after preoperative chemoradiotherapy in rectal cancer.
|
Anticancer Res
|
2011
|
0.85
|
|
34
|
Prognostic impact of VEGFA germline polymorphisms in patients with HER2-positive primary breast cancer.
|
Anticancer Res
|
2012
|
0.84
|
|
35
|
Expression of thymidylate synthase in primary colorectal adenocarcinoma.
|
Appl Immunohistochem Mol Morphol
|
2006
|
0.84
|
|
36
|
Elevated microRNA-126 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in colorectal cancer.
|
Oncol Lett
|
2011
|
0.84
|
|
37
|
Serum platelet-derived growth factor and fibroblast growth factor in patients with benign and malignant ovarian tumors.
|
Anticancer Res
|
2012
|
0.84
|
|
38
|
The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients.
|
Int J Gynecol Cancer
|
2012
|
0.84
|
|
39
|
Microsatellite instability and the association with plasma homocysteine and thymidylate synthase in colorectal cancer.
|
Cancer Invest
|
2008
|
0.84
|
|
40
|
Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer.
|
J Cancer Res Clin Oncol
|
2013
|
0.84
|
|
41
|
Transrectal ultrasound and magnetic resonance imaging measurement of extramural tumor spread in rectal cancer.
|
World J Gastroenterol
|
2012
|
0.83
|
|
42
|
Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer.
|
Int J Cancer
|
2014
|
0.83
|
|
43
|
Transrectal ultrasonography and magnetic resonance imaging in the staging of rectal cancer. Effect of experience.
|
Scand J Gastroenterol
|
2008
|
0.83
|
|
44
|
Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma.
|
Expert Rev Anticancer Ther
|
2011
|
0.83
|
|
45
|
Tumour hypoxia imaging with 18F-fluoroazomycinarabinofuranoside PET/CT in patients with locally advanced rectal cancer.
|
Nucl Med Commun
|
2013
|
0.83
|
|
46
|
Selection of colon cancer patients for neoadjuvant chemotherapy by preoperative CT scan.
|
Scand J Gastroenterol
|
2013
|
0.82
|
|
47
|
Prognostic importance of VEGF-A haplotype combinations in a stage II colon cancer population.
|
Pharmacogenomics
|
2012
|
0.81
|
|
48
|
Dose-response of acute urinary toxicity of long-course preoperative chemoradiotherapy for rectal cancer.
|
Acta Oncol
|
2014
|
0.81
|
|
49
|
Laser microdissection and microsatellite analysis of colorectal adenocarcinomas.
|
Anticancer Res
|
2006
|
0.81
|
|
50
|
The influence of tissue ischemia on biomarker expression in colorectal cancer.
|
Appl Immunohistochem Mol Morphol
|
2013
|
0.81
|
|
51
|
The prognostic value of microRNA-126 and microvessel density in patients with stage II colon cancer: results from a population cohort.
|
J Transl Med
|
2014
|
0.80
|
|
52
|
DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.
|
Int J Oncol
|
2007
|
0.80
|
|
53
|
Immunohistochemical expression of platelet-derived growth factor receptors in ovarian cancer patients with long-term follow-up.
|
Patholog Res Int
|
2012
|
0.79
|
|
54
|
Lack of the type III epidermal growth factor receptor mutation in colorectal cancer.
|
Anticancer Res
|
2007
|
0.79
|
|
55
|
Regulation of MLH1 mRNA and protein expression by promoter methylation in primary colorectal cancer: a descriptive and prognostic cancer marker study.
|
Cell Oncol (Dordr)
|
2013
|
0.79
|
|
56
|
Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study.
|
Int J Gynecol Cancer
|
2013
|
0.79
|
|
57
|
Estimation of immunohistochemical expression of VEGF in ductal carcinomas of the breast.
|
J Histochem Cytochem
|
2011
|
0.79
|
|
58
|
Visualising and quantifying angiogenesis in metastatic colorectal cancer : A comparison of methods and their predictive value for chemotherapy response.
|
Cell Oncol (Dordr)
|
2013
|
0.78
|
|
59
|
Quantitative analysis of vascular endothelial growth factor receptors 1 and 2 in colorectal cancer.
|
Mol Med Rep
|
2011
|
0.78
|
|
60
|
The prognostic value of haplotypes in the vascular endothelial growth factor a gene in colorectal cancer.
|
Cancers (Basel)
|
2010
|
0.78
|
|
61
|
A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas.
|
Acta Oncol
|
2010
|
0.78
|
|
62
|
Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study.
|
Int J Gynecol Cancer
|
2017
|
0.78
|
|
63
|
Protein kinase C-beta II (PKC-beta II) expression in patients with colorectal cancer.
|
Int J Colorectal Dis
|
2009
|
0.77
|
|
64
|
Gene expression of the mismatch repair gene MSH2 in primary colorectal cancer.
|
Tumour Biol
|
2011
|
0.77
|
|
65
|
HER1-4 protein concentrations in normal breast tissue from breast cancer patients are expressed by the same profile as in the malignant tissue.
|
Clin Chem Lab Med
|
2009
|
0.77
|
|
66
|
Immunohistological expression of HIF-1α, GLUT-1, Bcl-2 and Ki-67 in consecutive biopsies during chemoradiotherapy in patients with rectal cancer.
|
APMIS
|
2012
|
0.77
|
|
67
|
Quantitative detection of HER2 protein concentration in breast cancer tissue does not increase the number of patients eligible for adjuvant HER2-targeted therapy.
|
Oncol Rep
|
2013
|
0.77
|
|
68
|
Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study.
|
Gynecol Oncol
|
2003
|
0.76
|
|
69
|
Predictive value of MSH2 gene expression in colorectal cancer treated with capecitabine.
|
Clin Colorectal Cancer
|
2007
|
0.76
|
|
70
|
Predicting brain metastases of breast cancer based on serum S100B and serum HER2.
|
Oncol Lett
|
2013
|
0.76
|
|
71
|
Report of an early stopped randomized trial comparing cisplatin vs. cisplatin/ifosfamide/ 5-fluorouracil in recurrent cervical cancer.
|
Gynecol Obstet Invest
|
2004
|
0.76
|
|
72
|
Single nucleotide polymorphisms in the HIF-1α gene and chemoradiotherapy of locally advanced rectal cancer.
|
Oncol Lett
|
2012
|
0.76
|
|
73
|
The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection.
|
Int J Gynecol Pathol
|
2017
|
0.76
|
|
74
|
In reply to Fekete.
|
Int J Radiat Oncol Biol Phys
|
2013
|
0.75
|
|
75
|
Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer.
|
BMC Cancer
|
2010
|
0.75
|
|
76
|
[Treatment of cervix cancer with radical hysterectomy is a task for district departments].
|
Ugeskr Laeger
|
2006
|
0.75
|
|
77
|
TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
|
Tumour Biol
|
2015
|
0.75
|
|
78
|
Computed tomography assessment of early response to neoadjuvant therapy in colon cancer.
|
Dan Med J
|
2015
|
0.75
|
|
79
|
Limitations of tissue micro array in Duke's B colon cancer.
|
APMIS
|
2012
|
0.75
|
|
80
|
The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab.
|
Int J Gynecol Cancer
|
2016
|
0.75
|
|
81
|
Oral fluoropyrimidines in the treatment of advanced colorectal cancer--results of two consecutive phase II trials.
|
Acta Oncol
|
2002
|
0.75
|
|
82
|
[Radiation therapy, chemotherapy and watchful waiting as a treatment option in rectal cancer].
|
Ugeskr Laeger
|
2010
|
0.75
|
|
83
|
The prognostic importance of thymidylate gene polymorphism in colon cancer stage II.
|
Int J Colorectal Dis
|
2008
|
0.75
|
|
84
|
A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer.
|
Acta Oncol
|
2004
|
0.75
|